Literature DB >> 10581381

Treatment of cerebral Langerhans cell histiocytosis.

E Hund1, H Steiner, O Jansen, H Sieverts, G Sohl, M Essig.   

Abstract

Cerebral Langerhans cell histiocytosis (LCH) is a rare granulomatous disorder which may be primary or secondary or solitary or multiple. Brain structures outside the hypothalamic-pituitary axis are only scarcely involved, even in multisystem varieties. Since there are neither controlled therapeutic trials nor systematic analyses of hitherto reported cases, optimal treatment strategies are not known. To evaluate the effect of different treatment modalities, we analyzed previous reports of extrahypothalamic LCH back to 1980 in which the diagnosis was made on the basis of examination of cerebral tissues. Thirty-five histologically examined cases were identified, including 10 patients presenting with multiple cerebral lesions. Adding one own case followed up for 10 years, 16 patients had cerebral involvement secondary to multisystem LCH, while another 20 patients had primary cerebral LCH. The peak incidence was far beyond the pediatric range for both primary and secondary cerebral LCH. Localized lesions can be treated successfully by surgery or radiation following biopsy. Chemotherapy may be an additional option. Multiple lesions can tentatively be controlled by chemotherapy and, possibly, radiation. The ultimate outcome is determined by whether or not recurrencies or de-novo lesions will appear and the course of the systemic disease. Studies addressing the effects of therapy in cerebral LCH are urgently needed.

Entities:  

Mesh:

Year:  1999        PMID: 10581381     DOI: 10.1016/s0022-510x(99)00258-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.

Authors:  Toshihiko Imamura; Takashi Sato; Yoko Shiota; Hirokazu Kanegane; Kazuko Kudo; Shinichirou Nakagawa; Hisaya Nakadate; Hisamichi Tauchi; Junji Kamizono; Akira Morimoto
Journal:  Int J Hematol       Date:  2010-04-02       Impact factor: 2.490

2.  Three decades of progress from surgery to medical therapy for isolated neuroaxis BRAF V600E-positive Langerhans cell histiocytosis management: illustrative case.

Authors:  Nallammai Muthiah; Kamil W Nowicki; Jennifer L Picarsic; Michael P D'Angelo; Daniel F Marker; Edward G Andrews; Edward A Monaco; Ajay Niranjan
Journal:  J Neurosurg Case Lessons       Date:  2021-05-10

3.  MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis.

Authors:  Daniela Prayer; Nicole Grois; Helmut Prosch; Helmut Gadner; Anthony J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.